{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:51:27Z","timestamp":1768416687034,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U 10CA180868"],"award-info":[{"award-number":["U 10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ygyno.2015.11.024","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T17:41:08Z","timestamp":1448300468000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"140","author":[{"given":"Lisa M.","family":"Landrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan E.","family":"Tenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2015.11.024_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.024_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2015.11.024_bb0015","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.ygyno.2015.11.024_bb0020","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2015.11.024_bb0025","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9375","key":"10.1016\/j.ygyno.2015.11.024_bb0030","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.024_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ygyno.2015.11.024_bb0040","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6835","key":"10.1016\/j.ygyno.2015.11.024_bb0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.11.024_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bmb\/ldp005","article-title":"The potential role and application of PARP inhibitors in cancer treatment","volume":"89","author":"Chalmers","year":"2009","journal-title":"Br. Med. Bull."},{"issue":"20","key":"10.1016\/j.ygyno.2015.11.024_bb0055","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-09-0096","article-title":"Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair","volume":"15","author":"Bolderson","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2015.11.024_bb0060","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2015.11.024_bb0065","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2015.11.024_bb0070","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol. Asp. Med."},{"issue":"14","key":"10.1016\/j.ygyno.2015.11.024_bb0075","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","volume":"43","author":"Tentori","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2015.11.024_bb0080","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2015.11.024_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"issue":"13","key":"10.1016\/j.ygyno.2015.11.024_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2015.11.024_bb0095","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.024_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2015.11.024_bb0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2015.11.024_bb0110","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2013results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2015.11.024_bb0115","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2015.11.024_bb0120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2015.11.024_bb0125","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.11.024_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2015.11.024_bb0135","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.024_bb0140","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.024_bb0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.024_bb0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2012.05.028","article-title":"A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer","volume":"126","author":"Del Carmen","year":"2012","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T09:29:32Z","timestamp":1537176572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815301967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0090825815301967"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}